Forte Biosciences Investor Relations Material

Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company focuses on the development of first-in-class oral drugs for cancer, inflammation and fibrosis. Its lead product candidate is a dual inhibitor of chitin synthesis and metalloproteinases (NanoFol14) for the treatment of solid tumors including lung cancer, pancreatic cancer, glioblastoma and other cancers. The company is also developing ubenimex (a CCR5 antagonist), which is used for HIV entry inhibition; and an anti-angiogenesis drug for treating pancreatic cancer and other indications.